Evidence map›Paper›PMID 20107105›Full record

Trial reportDiabetes care2010

Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin.

Ralph A DeFronzo, Curtis Triplitt, Yongming Qu, Michelle S Lewis, David Maggs, Leonard C Glass

Open access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes care, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 6 pooled it
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 6 syntheses or guidelines pooled it, 103 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Intensive therapy in newly diagnosed type 2 diabetes: results of a 6-year randomized trial.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2014
    Trial
  8. Trial
  9. Trial
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH.International journal of molecular sciences · 2020
    Review
  17. Review
  18. GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019
    Review
  19. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research.Diabetes, metabolic syndrome and obesity : targets and therapy · 2017
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ralph A DeFronzoDivision of Diabetes, Department of Medicine, University of Texas Health Science Center, San Antonio, Texas, USA. albarado@uthscsa.edu
Curtis Triplitt
Yongming Qu
Michelle S Lewis
David Maggs
Leonard C Glass
Eli Lilly (United States) · USThe University of Texas Health Science Center at San Antonio · USAmplyx Pharmaceuticals (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveStudy the effects of exenatide (EXE) plus rosiglitazone (ROSI) on beta-cell function and insulin sensitivity using hyperglycemic and euglycemic insulin clamp techniques in participants with type 2 diabetes on metformin. RESEARCH DESIGN AND

methodsIn this 20-week, randomized, open-label, multicenter study, participants (mean age, 56 +/- 10 years; weight, 93 +/- 16 kg; A1C, 7.8 +/- 0.7%) continued their metformin regimen and received either EXE 10 microg b.i.d. (n = 45), ROSI 4 mg b.i.d. (n = 45), or EXE 10 microg b.i.d. + ROSI 4 mg b.i.d. (n = 47). Seventy-three participants underwent clamp procedures to quantitate insulin secretion and insulin sensitivity. RESULTS A1C declined in all groups (P < 0.05), but decreased most with EXE+ROSI (EXE+ROSI, -1.3 +/- 0.1%; ROSI, -1.0 +/- 0.1%, EXE, -0.9 +/- 0.1%; EXE+ROSI vs. EXE or ROSI, P < 0.05). ROSI resulted in weight gain, while EXE and EXE+ROSI resulted in weight loss (EXE, -2.8 +/- 0.5 kg; EXE+ROSI, -1.2 +/- 0.5 kg; ROSI, + 1.5 +/- 0.5 kg; P < 0.05 between and within all groups). At week 20, 1st and 2nd phase insulin secretion was significantly higher in EXE and EXE+ROSI versus ROSI (both P < 0.05). Insulin sensitivity (M value) was significantly higher in EXE+ROSI versus EXE (P = 0.014).

conclusionsTherapy with EXE+ROSI offset the weight gain observed with ROSI and elicited an additive effect on glycemic control with significant improvements in beta-cell function and insulin sensitivity.

Indexed as

AgedDiabetes Mellitus, Type 2Drug Therapy, CombinationExenatideFemaleGlucose Clamp TechniqueHumansHyperglycemiaHypoglycemic AgentsInsulinInsulin ResistanceInsulin-Secreting CellsInsulin SecretionMaleMetforminMiddle AgedExenatideHypoglycemic AgentsInsulinMetforminPeptidesRosiglitazoneThiazolidinedionesVenoms

Identifiers

PMID20107105
PMCPMC2858197
OpenAlexW2105926302

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.